false 0001658551 0001658551 2023-12-07 2023-12-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 7, 2023

 

 

AMYLYX PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-41199   46-4600503

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

43 Thorndike St.  
Cambridge, MA   02141
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 682-0917

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   AMLX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01. Regulation FD Disclosure.

On December 7, 2023, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) announced that Margaret Olinger will leave the Company as the Company’s Chief Commercial Officer effective as of end of day on December 31, 2023. The Company is engaged in a search for a new Chief Commercial Officer. Ms. Olinger’s departure is not related to any disagreement with Amylyx on any matter relating to its operations, policies, or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    AMYLYX PHARMACEUTICALS, INC.
Date: December 7, 2023     By:  

/s/ James M. Frates

      James M. Frates
      Chief Financial Officer
v3.23.3
Document and Entity Information
Dec. 07, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001658551
Document Type 8-K
Document Period End Date Dec. 07, 2023
Entity Registrant Name AMYLYX PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-41199
Entity Tax Identification Number 46-4600503
Entity Address, Address Line One 43 Thorndike St.
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code (617)
Local Phone Number 682-0917
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol AMLX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Amylyx Pharmaceuticals Charts.
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Amylyx Pharmaceuticals Charts.